Transcript Where Angels Feared to Tread

Where Angels Feared to Tread
Roger Ashby
Hunter-Fleming Ltd
Technology Transfer
• Experience from both sides
• Hunter-Fleming, an example
• Working with universities
HUNTER FLEMING
PHARMACEUTICAL PIPELINE PROVIDERS
 Hunter-Fleming Ltd
Mission
To be a leading, highly profitable, international company
supplying novel breakthrough prescription medicines to
global marketing companies, in areas of significant unmet
medical needs.
PATENT TO PATIENT
 Hunter-Fleming Ltd
S
an
o
t
K
ot
fiz
er
J
M
ar
tis
yn
th
el
ab
o
B
ay
er
ca
er
ck
N
ov
W
ye
th
P
J&
A
st
ra
Ze
ne
fiS
 Hunter-Fleming Ltd
A
ve
nt
is
A
bb
G
S
The Market
250
200
Under Licence
Own Drugs
150
100
50
0
Management
• Giles Vardy, Non Exec Chairman, Chairman of AIM
Steering Group, former CEO of Greig Middleton,
Chairman CQS Management, alternative asset
management business
• Dr Jim Murray, CEO: co-founder of Shire, 29 years in
Pharma industry
• Professor Ernst Wulfert, CSO: former Research Director
UCB responsible for the development of three
blockbuster drugs – Keppra, Zyrtec, enofibrate
• Dr. John Fox, Managing Director: Head of Planning at
Shire, 20 years in pharmacology & clinical research
• Neil Hockaday, FD: COO HSBC Corporate Banking
 Hunter-Fleming Ltd
University Collaborations
•
•
•
•
•
•
•
•
•
 Hunter-Fleming Ltd
Bristol
Belfast
Southampton
St Marianna Hospital, Medical School,
Kawasaki
Loyola, Chicago
CNAM, Paris
Kyoto Pharmaceutical University, Japan
Tromso, Norway
Strathclyde/Glasgow
Business Model
VALUE
C
NDA, drug filing
B
“Innovations
Break Point”
Basic
Discovery
A
COST
Basic Research
ACADEMIA
Innovation
HF
 Hunter-Fleming Ltd
Drug Development
BIG PHARMA
Integrated Therapies
anti-neurodegenerative drugs
(brain inflammatory diseases)
HF 0220
Neurosciences
Immunology &
Inflammation
(RA, Type I diabetes,
(neurodegenerative
diseases, AD, PD, stroke,
MS…)
asthma, rhinitis, cancer..)
Cardiovascular &
Metabolic Disorders
(CHD, MI, Diabetes…)
Anti-diabetic
HF 1020
 Hunter-Fleming Ltd
Novel cytoprotective drugs
brain, heart, kidney
HF 0220 “follow-ups”
Portfolio
Preclinical
HF0220
Alzheimer’s Disease
HF0220 2nd generation
HF1020
IBD, RA
Type I Diabetes
HF0699
Head Injury/Stroke
HF0420
Neuro Protective/Alzheimer’s disease
HF0299
Metabolic bone disease
HF0723
Oncology
 Hunter-Fleming Ltd
Phase I
Phase II
Phase III
WHY ?
• Access to blue sky research
• Access to intellectual property
• Access to ongoing research output
FACT
• British Telecom research spend £30m pa
• Bristol University,
• UCL, Imperial College,
• Southampton University
-
£500m pa
ACADEMIA
Solutions seeking applications
INDUSTRY
Paucity of innovative knowledge
cf Pharma 50% all new medicines
in-licensed
KEY ISSUES
•
•
•
•
•
Point of contact
Executive authority
Ability to deliver – Willing scientists
- Secured IP
Continuity
Deal Breakers
• Valuation of IP and / or Know how
• Limitation of management expertise
Decision
• Licence OR
• Start up new company
Hunter-Fleming
•
•
•
•
•
•
•
•
Mature management team
Proven track record
Understand university’s modus operandi
Enduring partnership
Virtual circle taking IP to market
Financial returns to all- University
- Research Staff
- H-F shareholders